正文
Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73(6): 1368-1378. DOI: 10.1016/j.jhep.2020.07.025.
[8]
Russo FP, Imondi A, Lynch EN, et al. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review[J]. Dig Liver Dis, 2018, 50(7): 640-646. DOI: 10.1016/j.dld.2018.03.014.
[9]
Li L, Zou X, Zheng W, et al. Contrast-enhanced US with sulfur hexafluoride and perfluorobutane: LI-RADS for diagnosing hepatocellular carcinoma[J]. Radiology, 2023, 308(2): e230150. DOI: 10.1148/radiol.230150.
[10]
Khalili K, Kim TK, Jang HJ, et al. Optimization of imaging diagnosis of 1-2cm hepatocellular carcinoma: an analysis of diagnostic performance and resource utilization[J]. J Hepatol, 2011, 54(4): 723-728. DOI: 10.1016/j.jhep.2010.07.025.
[11]
Ren J, Lu Q, Fei X, et al. Assessment of arterial-phase hyperenhancement and late-phase washout of hepatocellular carcinoma-a meta-analysis of contrast-enhanced ultrasound (CEUS) with SonoVue® and Sonazoid®[J]. Eur Radiol, 2023. DOI: 10.1007/s00330-023-10371-2.
[12]
Huang J, Chen W, Yao S. Assessing diagnostic value of contrast-enhanced ultrasound and contrast-enhanced computed tomography in detecting small hepatocellular carcinoma: a meta-analysis[J]. Medicine, 2017, 96(30): e7555. DOI: 10.1097/MD.0000000000007555.
[13]
Bo X, Xu H, Wang D, et al. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers[J]. Br J Radiol, 2016, 89(1067): 20160379. DOI: 10.1259/bjr.20160379.
[14]
Tang M, Li Y, Lin Z, et al. Hepatic nodules with arterial phase hyperenhancement and washout on enhanced computed tomography/magnetic resonance imaging: how to avoid pitfalls[J]. Abdom Radiol (NY), 2020, 45(11): 3730-3742. DOI: 10.1007/s00261-020-02560-0.
[15]
Joo I, Lee JM, Lee DH, et al. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?[J]. Eur Radiol, 2019, 29(4): 1724-1732. DOI: 10.1007/s00330-018-5727-1.
[16]
Roth CG, Mitchell DG. Hepatocellular carcinoma and other hepatic malignancies: MR imaging[J]. Radiol Clin North Am, 2014, 52(4): 683-707. DOI: 10.1016/j.rcl.2014.02.015.
[17]
Han D, Li Y, He X, et al. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus[J]. Quant Imaging Med Surg, 2023, 13(10): 7156-7169. DOI: 10.21037/qims-23-396.
[18]
Liu X, Jiang H, Chen J, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: a meta-analysis[J]. Liver Transpl, 2017, 23(12): 1505-1518. DOI: 10.1002/lt.24867.
[19]
Zhang L, Ge N, Chen Y, et al. Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients[J]. Med Oncol, 2015, 32(3): 77. DOI: 10.1007/ s12032-015-0532-z.
[20]
Yu MH, Kim JH, Yoon JH, et al. Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging[J]. Radiology, 2014, 271(3): 748-760. DOI: 10.1148/radiol. 14131996.
[21]
饶圣祥, 张岚. 《原发性肝癌诊疗指南（2024年版）》影像诊断更新解读——聚焦亚厘米肝癌的诊断[J]. 中国医学影像学杂志, 2024, 32(6): 529-532. DOI: 10.3969/j.issn. 1005-5185.2024.06.001.
[22]
Ueno S, Tanabe G, Nuruki K, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis[J]. Hepatol Res, 2002, 24(4): 395-403. DOI: 10.1016/S1386-6346(02)00144-4.
[23]
Koga H, Iwamoto H, Suzuki H, et al. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Japanese perspective[J]. Clin Mol Hepatol, 2023, 29(2): 242-251. DOI: 10.3350/cmh.2023.0102.
[24]
Vitale A, Farinati F, Finotti M, et al. Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications[J]. Cancers, 2021, 13(7): 1673. DOI: 10.3390/cancers13071673.
